RG-12525  ≥98%

促销价¥{{model.attbuying.price}}

市场价¥0.00

累计销量0 累计评价0 人评论

别称 {{model.alias}}
中文名称 {{model.name}}
英文名称 {{model.enname}}
品牌 {{model.brand}}
CAS {{model.cas}}
分子式
分子量 {{model.molecularweight}}
MDL {{model.mdl}}
货号 {{model.procode}}
数量

+ -

库存{{model.attbuying.number}}
包装规格:1mg 5mg 10mg in glass bottle
溶解性:溶于DMSO(25mg/ml超声)
产品描述:基本信息 产品编号: R10404 产品名称: RG-12525 CAS: 120128-20-3   储存条件 粉末 -20℃ 四年     分子式: C25H21N5O2 溶于液体 -80℃ 6个月 分子量: 423.47 -20℃ 1个月 化学名:  2-((4-((2-(1H-Tetrazol-5-ylmethyl)phenyl)methoxy)phenoxy)methyl)quinoline Solubility (25°C):   体外:   DMSO   Ethanol   Water   体内(现配现用):   <1mg/ml表示微溶或不溶。 普西唐提供的所有化合物浓度为内部测试所得,实际溶液度可能与公布值有所偏差,属于正常的批间细微差异现象。 请根据产品在不同溶剂中的溶解度选择合适的溶剂配制储备液;⼀旦配成溶液,请分装保存,避免反复冻融造成的产品失效。   制备储备液   浓度   溶液体积 质量   1mg   5mg   10mg 1mM 2.3614mL 11.8072mL 23.6144mL 5mM 0.4723mL 2.3614mL 4.7229mL 10mM 0.2361mL 1.1807mL 2.3614mL   生物活性 产品描述 一种特异性的,竞争性的,可口服的LTC4,LTD4和LTE4拮抗剂 靶点 Leukotriene Receptor PPAR Cytochrome P450   体外研究 RG 12525 competitively inhibits 3H-LTD4 binding to lung membranes (Ki=3.0 +/- 0.3nM) and competitively antagonizes the spasmogenic activity of LTC4,LTD4 and LTE4 on lung strips (KB values=3nM) with greater than 8000 fold selectivity.RG 12525 (2.5µM or 25µM) inhibits the microsomal activity of CYP2C9 and -3A4,but does not significantly inhibit CYP1A2,-2A6,-2C19,or -2D6.RG 12525 (25µM) also causes a substantial amount of inhibition at the 5 and 10µM midazolam concentrations. 体内研究 RG 12525 orally inhibits LTD4 induced wheal formation (ED50=5mg/kg with a t1/2=10 hrs at 9mg/kg),LTD4 induces bronchoconstriction (ED50=0.6mg/kg),and anaphylactic death (ED50=2.2mg/kg with a t1/2=7 hrs at 10mg/kg) and antigen induces bronchoconstriction (ED50=0.6mg/kg).RG 12525 inhibits antigen-induced mortality in the systemic anaphylaxis model with an ED50 (95% confidence interval)=2.2 (0.8-6.4)mg/kg.RG 12525 also protects against LTD4-induced bronchoconstriction in a model measuring changes in pulmonary function with an ED50=0.6 (0.4-1.0)mg/kg.
保存条件:-20℃